Indeed, treatment of NSCLC cells (A549) with cancer patients EV elevated WNT and AKT signaling levels compared to the effect of EV from screening controls, as determined by β-catenin and phospho-AKT protein levels, respectively (Fig. 3e,f, and Supplementary Information 3). The gene discussed is AKT1; the disease is cancer.